The Role of Vitamin K on Knee Osteoarthritis Outcomes

Summary

The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known, The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.

Eligibility

Age range

60+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Vitamin K1 500 µg

  One pill daily for 4 weeks.

• Drug
  K1 1000 µg

  One pill daily for 4 weeks.

• Drug
  Vitamin K2 (MK-7) 300 µg

  One pill daily for 4 weeks.

• Other
  Placebo

  Placebo pill daily for 4 weeks.

Location